Phathom Pharmaceuticals Inc expected to post a loss of $1.35 a share - Earnings Preview

Phathom Pharmaceuticals

24/02/2023 11:08

* Phathom Pharmaceuticals Inc  PHAT.OQ   PHAT.O  is expected
to show no change in quarterly revenue when it reports 
results on February 27 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Phathom
Pharmaceuticals
Inc is for a loss of $1.35 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Phathom
Pharmaceuticals Inc is $22.5​, above​ its last closing price
of $9.95. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -1.32       -1.32      -1.32     Met     -0.2
 Jun. 30 2022  -0.99       -1.03      -1.33     Missed  -29.1
 Mar. 31 2022  -0.98       -0.97      -1.07     Missed  -10.5​
 Dec. 31 2021  -1.05       -1.03      -0.95     Beat    7.6
 ​​Sep.        -1.01       -0.98      -0.98     Met     0
 30 2021                                                
 Jun. 30 2021  -1.07       -1.07      -1.00     Beat    6.4​
 Mar. 31 2021  -1.18       -1.19      -0.96     Beat    19.2
 Dec. 31 2020  -0.99       -1.01      -1.58     Missed  -56.2
 This summary was machine generated February 24 at 11:08 GMT. 
All figures in US dollars  unless otherwise stated